Lixte Biotechnology (LIXT) Competitors

$4.49 +1.20 (+36.47%)

Closing price 04:00 PM Eastern

Extended Trading

$4.47 -0.02 (-0.36%)

As of 05:45 PM Eastern

LIXT vs. PRQR, TLSA, ORMP, GALT, and BDTX

Should you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include ProQR Therapeutics (PRQR), Tiziana Life Sciences (TLSA), Oramed Pharmaceuticals (ORMP), Galectin Therapeutics (GALT), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry.

How does Lixte Biotechnology compare to ProQR Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

: ProQR Therapeutics currently has a consensus target price of $7.25, suggesting a potential upside of 344.79%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe ProQR Therapeutics is more favorable than Lixte Biotechnology.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProQR Therapeutics
1 Sell rating(s)
1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.63
Lixte Biotechnology
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Lixte Biotechnology has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -255.83%. ProQR Therapeutics' return on equity of -65.89% beat Lixte Biotechnology's return on equity.
Company Net Margins Return on Equity Return on Assets
ProQR Therapeutics -255.83% -65.89% -31.53%
Lixte Biotechnology N/A -242.85% -115.18%
: 32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 9.5% of Lixte Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: Lixte Biotechnology has lower revenue, but higher earnings than ProQR Therapeutics. Lixte Biotechnology is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ProQR Therapeutics $15.91M 10.80 -$47.73M -$0.46 N/A
Lixte Biotechnology N/A N/A -$6.01M -$1.24 N/A
: In the previous week, ProQR Therapeutics had 3 more articles in the media than Lixte Biotechnology. MarketBeat recorded 3 mentions for ProQR Therapeutics and 0 mentions for Lixte Biotechnology. ProQR Therapeutics' average media sentiment score of 0.64 beat Lixte Biotechnology's score of -1.32 indicating that ProQR Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
ProQR Therapeutics Positive
Lixte Biotechnology Negative
: ProQR Therapeutics has a beta of 0.08, meaning that its share price is 92% less volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-255.83%	-65.89%	-31.53%
Lixte Biotechnology	N/A	-242.85%	-115.18%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$15.91M	10.80	-$47.73M	-$0.46	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.24	N/A

Company	Overall Sentiment
ProQR Therapeutics	Positive
Lixte Biotechnology	Negative

Summary

ProQR Therapeutics beats Lixte Biotechnology on 11 of the 15 factors compared between the two stocks.

How does Lixte Biotechnology compare to Tiziana Life Sciences?

Tiziana Life Sciences (NASDAQ:TLSA) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tiziana Life Sciences N/A N/A -$18.43M N/A N/A
Lixte Biotechnology N/A N/A -$6.01M -$1.24 N/A
: In the previous week, Tiziana Life Sciences had 2 more articles in the media than Lixte Biotechnology. MarketBeat recorded 2 mentions for Tiziana Life Sciences and 0 mentions for Lixte Biotechnology. Tiziana Life Sciences' average media sentiment score of 0.54 beat Lixte Biotechnology's score of -1.32 indicating that Tiziana Life Sciences is being referred to more favorably in the media.
Company Overall Sentiment
Tiziana Life Sciences Positive
Lixte Biotechnology Negative
: 5.1% of Lixte Biotechnology shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by company insiders. Comparatively, 9.5% of Lixte Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: Tiziana Life Sciences' return on equity of 0.00% beat Lixte Biotechnology's return on equity.
Company Net Margins Return on Equity Return on Assets
Tiziana Life Sciences N/A N/A N/A
Lixte Biotechnology N/A -242.85% -115.18%
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tiziana Life Sciences
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Lixte Biotechnology
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Tiziana Life Sciences has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.24	N/A

Company	Overall Sentiment
Tiziana Life Sciences	Positive
Lixte Biotechnology	Negative

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Lixte Biotechnology	N/A	-242.85%	-115.18%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Tiziana Life Sciences beats Lixte Biotechnology on 5 of the 8 factors compared between the two stocks.

How does Lixte Biotechnology compare to Oramed Pharmaceuticals?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

: 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are owned by institutional investors. 17.8% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 9.5% of Lixte Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: Oramed Pharmaceuticals has higher revenue and earnings than Lixte Biotechnology. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oramed Pharmaceuticals $2M 80.49 $64.05M $1.49 2.67
Lixte Biotechnology N/A N/A -$6.01M -$1.24 N/A
: Oramed Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.
: Oramed Pharmaceuticals' return on equity of -6.83% beat Lixte Biotechnology's return on equity.
Company Net Margins Return on Equity Return on Assets
Oramed Pharmaceuticals N/A -6.83% -6.25%
Lixte Biotechnology N/A -242.85% -115.18%
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oramed Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
Lixte Biotechnology
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: In the previous week, Oramed Pharmaceuticals' average media sentiment score of 0.00 beat Lixte Biotechnology's score of -1.32 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.
Company Overall Sentiment
Oramed Pharmaceuticals Neutral
Lixte Biotechnology Negative

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	80.49	$64.05M	$1.49	2.67
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.24	N/A

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-6.83%	-6.25%
Lixte Biotechnology	N/A	-242.85%	-115.18%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Overall Sentiment
Oramed Pharmaceuticals	Neutral
Lixte Biotechnology	Negative

Summary

Oramed Pharmaceuticals beats Lixte Biotechnology on 11 of the 11 factors compared between the two stocks.

How does Lixte Biotechnology compare to Galectin Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

: 11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by insiders. Comparatively, 9.5% of Lixte Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
: Galectin Therapeutics is trading at a lower price-to-earnings ratio than Lixte Biotechnology, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Galectin Therapeutics N/A N/A -$30.84M -$0.48 N/A
Lixte Biotechnology N/A N/A -$6.01M -$1.24 N/A
: Galectin Therapeutics has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.
: Galectin Therapeutics' return on equity of 0.00% beat Lixte Biotechnology's return on equity.
Company Net Margins Return on Equity Return on Assets
Galectin Therapeutics N/A N/A -214.23%
Lixte Biotechnology N/A -242.85% -115.18%
: Galectin Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 393.27%. Given Galectin Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Galectin Therapeutics is more favorable than Lixte Biotechnology.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galectin Therapeutics
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Lixte Biotechnology
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: In the previous week, Galectin Therapeutics' average media sentiment score of 0.00 beat Lixte Biotechnology's score of -1.32 indicating that Galectin Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Galectin Therapeutics Neutral
Lixte Biotechnology Negative

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.48	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.24	N/A

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-214.23%
Lixte Biotechnology	N/A	-242.85%	-115.18%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Overall Sentiment
Galectin Therapeutics	Neutral
Lixte Biotechnology	Negative

Summary

Galectin Therapeutics beats Lixte Biotechnology on 8 of the 12 factors compared between the two stocks.

How does Lixte Biotechnology compare to Black Diamond Therapeutics?

Lixte Biotechnology (NASDAQ:LIXT) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

: Black Diamond Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 248.43%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Lixte Biotechnology.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lixte Biotechnology
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Black Diamond Therapeutics
1 Sell rating(s)

2 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
2.70
: In the previous week, Black Diamond Therapeutics had 9 more articles in the media than Lixte Biotechnology. MarketBeat recorded 9 mentions for Black Diamond Therapeutics and 0 mentions for Lixte Biotechnology. Black Diamond Therapeutics' average media sentiment score of 1.05 beat Lixte Biotechnology's score of -1.32 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
Lixte Biotechnology Negative
Black Diamond Therapeutics Positive
: 5.1% of Lixte Biotechnology shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 9.5% of Lixte Biotechnology shares are held by insiders. Comparatively, 6.0% of Black Diamond Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Black Diamond Therapeutics has higher revenue and earnings than Lixte Biotechnology. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lixte Biotechnology N/A N/A -$6.01M -$1.24 N/A
Black Diamond Therapeutics $70M 2.35 $22.37M $0.37 7.76
: Lixte Biotechnology has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 3.34, meaning that its share price is 234% more volatile than the S&P 500.
: Black Diamond Therapeutics' return on equity of 23.19% beat Lixte Biotechnology's return on equity.
Company Net Margins Return on Equity Return on Assets
Lixte Biotechnology N/A -242.85% -115.18%
Black Diamond Therapeutics N/A 23.19% 18.48%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70

Company	Overall Sentiment
Lixte Biotechnology	Negative
Black Diamond Therapeutics	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.24	N/A
Black Diamond Therapeutics	$70M	2.35	$22.37M	$0.37	7.76

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-242.85%	-115.18%
Black Diamond Therapeutics	N/A	23.19%	18.48%

Summary

Black Diamond Therapeutics beats Lixte Biotechnology on 14 of the 15 factors compared between the two stocks.

Get Lixte Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIXT vs. The Competition

Export

Metric	Lixte Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$52.17M	$3.39B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	-3.62	38.85	29.04	28.47
Price / Sales	N/A	155.51	476.61	60.92
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	4.28	7.03	9.67	6.67
Net Income	-$6.01M	$23.62M	$3.55B	$332.53M
7 Day Performance	24.72%	3.68%	1.70%	2.01%
1 Month Performance	47.21%	7.16%	5.62%	9.19%
1 Year Performance	253.54%	67.05%	34.41%	39.59%

Lixte Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIXT Lixte Biotechnology	0.3311 of 5 stars	$4.49 +36.5%	N/A	N/A	$52.17M	N/A	N/A	4	Negative News Upcoming Earnings High Trading Volume
PRQR ProQR Therapeutics	3.3713 of 5 stars	$1.54 +4.1%	$7.25 +370.8%	N/A	$162.26M	$15.91M	N/A	180	Gap Up High Trading Volume
TLSA Tiziana Life Sciences	0.0515 of 5 stars	$1.26 +0.8%	N/A	N/A	$160.35M	N/A	N/A	8	Positive News Earnings Report
ORMP Oramed Pharmaceuticals	1.405 of 5 stars	$3.84 -4.7%	N/A	N/A	$155.31M	$2M	2.58	10
GALT Galectin Therapeutics	1.2795 of 5 stars	$2.25 -3.0%	$11.00 +388.9%	N/A	$148.12M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIXT) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lixte Biotechnology (LIXT) Competitors

LIXT vs. PRQR, TLSA, ORMP, GALT, and BDTX

How does Lixte Biotechnology compare to ProQR Therapeutics?

Summary

How does Lixte Biotechnology compare to Tiziana Life Sciences?

Summary

How does Lixte Biotechnology compare to Oramed Pharmaceuticals?

Summary

How does Lixte Biotechnology compare to Galectin Therapeutics?

Summary

How does Lixte Biotechnology compare to Black Diamond Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIXT vs. The Competition

Lixte Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lixte Biotechnology (LIXT) Competitors

LIXT vs. PRQR, TLSA, ORMP, GALT, and BDTX

How does Lixte Biotechnology compare to ProQR Therapeutics?

Summary

How does Lixte Biotechnology compare to Tiziana Life Sciences?

Summary

How does Lixte Biotechnology compare to Oramed Pharmaceuticals?

Summary

How does Lixte Biotechnology compare to Galectin Therapeutics?

Summary

How does Lixte Biotechnology compare to Black Diamond Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIXT vs. The Competition

Lixte Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools